Trial Profile
A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms TERRANOVA
- Sponsors AstraZeneca
- 02 Apr 2020 Results doing integrated analyses of benralizumab safety data from the phase III SIROCCO and CALIMA trials and subsequent BORA extension trial and ZONDA for patients with asthma, and the phase III GALATHEA and TERRANOVA trials for patients with chronic obstructive pulmonary disease, published in the Drug Safety
- 29 Sep 2019 Results presented in an AstraZeneca media telease
- 29 Sep 2019 According to an AstraZeneca media release, pooled and individual data from this and other trial were presented at the European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain.